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Acute graft-versus-host disease (aGVHD) can be triggered by inﬂammatory conditions, including infections
and mucositis. We investigated the association between PCR positivity for gastrointestinal (GI) viruses in stool
before hematopoietic cell transplantation (HCT) and intestinal aGVHD using Cox proportional hazard models.
We included 48 consecutive HCT patients (28 with malignancies and 20 with nonmalignancies) without GI
symptoms before HCT. Fifteen patients were GI virus positive: 9 adenovirus, 3 norovirus, 2 parechovirus, and
1 astrovirus. Overall survival was 58%  8%. The cumulative incidence of aGVHD grade 2 to 4 was 43%  8%
(n ¼ 18) after a median of 47 days (range, 14 to 140). In univariate analysis, GI virus PCR positivity was the
only predictor for aGVHD (P ¼ .008): within the group of GI virus PCR-positive patients, the cumulative
incidence of aGVHD 2 to 4 was 70%  12% versus 29  8% in the PCR-negative group (P ¼ .004). In conclusion,
GI virus PCR positivity before HCT predicted development of intestinal aGVHD. These results may ultimately
affect monitoring, aGVHD prophylaxis, and treatment, as well as rescheduling of elective HCTs.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Acute graft-versus-host disease (aGVHD) is a common
(20% to 50%) [1-3] and life-threatening complication after
allogeneic hematopoietic cell transplantation (HCT), associ-
ated with severe morbidity and mortality. Risk factors for
aGVHD include stem cell source, preparative regimen, and
degree of HLA mismatching [4]. Although the pathogenesis
of GVHD is complex and not completely understood, it is well
known that tissue damage is a risk factor for the initiation of
GVHD. Conditioning-induced toxicity, infections, and in
some cases the underlying disease can all induce tissue
inﬂammation in the host, leading to activation of antigen-
presenting cells and innate immune cells, eventually fol-
lowed by a T celledriven allo-immune reaction. Currently,
there is increasing evidence that (reactivation of) viral
infection is a risk factor for aGVHD [5]; however, the role of
common gastrointestinal (GI) viruses in the pathogenesis of
intestinal aGVHD (especially in the gut) has not been studied
widely.
We hypothesized that the presence of common viruses in
the GI tract (eg, adenovirus and norovirus) predisposes the
host to intestinal GVHD. Therefore, we studied the associa-
tion between PCR positivity of GI viruses in stool before HCT
and the subsequent occurrence of intestinal aGVHD.
METHODS
We evaluated a cohort of 48 consecutive pediatric allogeneic HCT pa-
tients without GI symptoms from January 2009 until October 2010. Patientsedgments on page 774.
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15.01.009who died before engraftment were considered nonevaluable and were
excluded from the analyses (n ¼ 1). Parents and patients signed informed
consent for HCT including data collection and bio banking. Stool specimens
were taken once during the conditioning period before HCT (ie, between day
-10 and day -1 before HCT, with none of the patients receiving antiviral
medication at that moment). Stool specimens were taken bimonthly during
the ﬁrst 6 months of follow-up as part of our routinemonitoring protocol for
viral infections.Detection of Enteric Viruses
Stool samples were analyzed by real-time PCR in duplicate for the
presence of enterovirus, norovirus, astrovirus, parechovirus, and adenovirus
as described previously [6]. The enterovirus PCR detects poliovirus 1, 2, and
3, and a total of 58 subtypes of the human enteroviruses groups A, B, C, and
D. Stool samples were tested for antigens of rotavirus by ELISA using the
Oxoid ProSpecT rotavirus microplate assay (Oxoid Ltd, Hampshire, UK). Stool
samples were considered positive (GI-PCR positivity) for any of these viruses
in case a positive test result by PCR was reached after < 35 PCR cycles.Transplantation, Conditioning, and Supportive Care
All patients who underwent transplantation for acute lymphatic leu-
kemia were conditioned with total body irradiation. Matched unrelated
donors and cord blood recipients received antithymocyte globulin as sero-
therapy, in addition to myeloablative conditioning with busulfan (targeted
exposure) and ﬂudarabine. Antibiotic prophylaxis was started in parallel
with the conditioning regimen, administering ciproﬂoxacillin and ﬂucona-
zole until patients recovered from neutropenia. Pneumocystis jerovecii pro-
phylaxis was started 1 month after transplantation with cotrimoxazole
3 days per week. Antiviral prophylaxis (acyclovir) was given routinely until
engraftment and extended to ganciclovir or foscarnet in cases of cytomeg-
alovirus (CMV)- seropositive recipients with high risk of CMV reactivation.
GVHD prophylaxis consisted of cyclosporine, supplemented with prednis-
olone for cord blood transplantations or methotrexate in unrelated donor or
peripheral blood stem cell transplantations. Thymoglobulin (Genzyme,
Cambridge, MA) was given to patients who received an unrelated donor
graft (in cord blood from day -9 until -6, in matched unrelated donor set-
tings from day -5 until -1). All patients with a diarrhea volume of >500 cc
per day underwent GI tract biopsies in the upper and lower GI tract, as part
of institutional work-up in post-HCT patients with extensive diarrhea. GVHD
was managedwith intensiﬁcation of immunosuppressive therapy, following
institutional therapeutic guidelines.
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The primary endpoint was the development of intestinal aGVHD diag-
nosed according to Gluckberg’s criteria [7] and conﬁrmed by histopathology
and by exclusion of an infectious cause of diarrhea. Exclusion of infectious
causes of diarrhea was established by negative PCR results for the following
pathogens: Salmonella spp, Shigella spp, Yersinia spp, Campylobacter spp,
Giardia spp, Dientamoeba spp, Cryptosporidium spp, and Clostridium spp.
We found no new cases of viral PCR positivity in patients with diarrhea
besides the cases that were viral-PCR positive before HCT. The secondary
endpoint was overall survival (OS). We analyzed predictors for the occur-
rence of aGVHD and survival using Cox proportional hazard models. The
following possible variables were evaluated: age at transplantation, gender,
category of underlying disease, donor source, anticipated transplantation-
related mortality risk (< or > 20%) [8], donor source, HLA disparity, condi-
tioning regimen, and the presence of any GI virus in stool before HCT.
Cumulative incidence estimates were calculated for neutrophil recovery and
aGVHD and chronic GVHD (cGVHD) with death as the competing event. Gray
tests were used for univariate comparisons. Probabilities of event-free sur-
vival and OS were calculated using Kaplan-Meier estimates. Multivariate
analyses were not performed as there were no other factors besides virus
positivity with a P value less than .10 by univariate analysis. Statistical an-
alyses were performed with SPSS (Inc., Chicago, IL) and S-Plus (MathSoft,
Inc, Seattle, WA) software packages.
RESULTS
Of 48 patients included (28 with malignancies and 20
with nonmalignancies), 15 patients were found PCR positive
for any virus in their stool samples before HCT: 9 adenovirus,
3 norovirus, 2 parechovirus and 1 astrovirus (Table 1).Within
the group of adenovirus-positive patients, 5 patients were
positive for multiple viruses: adenovirus þ enterovirus
(n ¼ 2), adenovirus þ norovirus (n ¼ 2), and
adenovirusþ norovirusþ parechovirus (n¼ 1). Nine patients
received antiviral therapy because of viral reactivation (or
multiple viral reactivations) of herpes viruses and/or
adenovirus: 7 patients received foscarnet (6 for CMV and 1
for human herpesviruse6 reactivation) at a medium time
after HCT of 38 days. Two patients received cidofovir for
combined viral reactivation of CMV and adenovirus.
The overall survival was 58%  8% within this cohort after
a median follow-up of 670 (range, 24 to 1350) days. All pa-
tients in this cohort achieved donor chimerism> 95% (on fullTable 1
Clinical Characteristics of Study Patients (N ¼ 48)
Patient Characteristics GI-Virus PCR
Negative
GI-Virus
PCR Positive
P Value
Age at Tx, median
(range), yr
11.2 (.16-22.7) 3.06 (.85-17.4) .432
Follow-up time, median
(range), d
588 (1-1275) 607 (59-1350) .392
Gender
Male 20 9
Female 13 6 .968
Anticipated TRM risk
>20% 22 11
<20% 11 4 .644
Transplantation number
First 32 14
Second 1 1 .599
Indication for HCT
Malignant diseases 20 8
Nonmalignant diseases 13 7 .636
Donor
MSD 7 1
Unrelated CB 21 12
Unrelated marrow 5 2 .420
Match grade
Matched 21 7
Mismatched 12 8 .499
Tx indicates transplantation; TRM, transplantation-related mortality; MSD,
matched sibling donor; CB, cord blood.blood) between day 30 and 40 after HCT. Eighteen patients
developed aGVHD grade 2 through 4 (all with GI involve-
ment, conﬁrmed by histopathology), and the cumulative
incidence of aGVHD grade 2 through 4 was 42%  8% after a
median of 47 days (range, 14 to 140).
Liver GVHDwas noted in 2 out of 16 overall grade II GVHD
patients. Skin GVHD was noted in 14 of 16 patients. GI GVHD
was noted in the following frequencies: grade I, n ¼ 7; grade
II, n ¼ 4; grade III, n ¼ 3; and grade IV, n ¼ 2.
In univariate analysis, GI virus PCR positivity was the only
predictor for acute intestinal GVHD (P ¼ .008; other possible
predictors P > .18) (Table 2). Within the group of GI virus
PCR-positive patients, the cumulative incidence of intestinal
aGVHD 2 to 4 was 70%  12%, and in the group of GI-virus
PCR-negative patients, 29%  8% (P ¼ .004) (Figure 1).
There was no impact of viral status on cGVHD: the overall
probability at 1 year after HCT of cGVHD was 11%, and no
difference was found between the 2 groups (P ¼ .585).
Further, GVHD in this cohort did not affect overall OS. Causes
of death were as follows in 10 patients: GVHD, 10%; invasive
fungal infection, 10%; multiorgan failure, 40%; noninfectious
lung injury, 20%; viral reactivation, 10%; and viral lung injury,
10%. In 3 patients who died of multiorgan failure, GVHD was
a cofactor.
In all patients who were viral PCR positive before HCT,
PCRs remained positive for the same viruses for >3 months
after HCT. OS was not signiﬁcantly inﬂuenced by any vari-
able, including aGVHD.DISCUSSION
We found that GI virus PCR positivity in stool before HCT
was a predictor for the development of intestinal acute-
GVHD. This ﬁnding supports the hypothesis that mucosal
tissue damage [9] (in this situation due to viral persistence)
during early immune reconstitution gives rise to an inﬂam-
matory trigger for the immune system, which ultimately
causes activation and inﬂux of activated cytotoxic T cells
involved in GVHD. The OS in this cohort was not inﬂuenced
by GVHD, which may be due the relative small cohort size.
Bacterial intestinal ﬂora (microbiomes) have been shown
to be associated with susceptibility for aGVHD [10-14]. TheTable 2
Univariate Analysis of Predictors of aGVHD Grade 2 to 4
Predictors Hazard Ratio 95% CI P Value
Age at HCT (continue) .96 .89-1.036 .315
TRM risk
<20% 1
>20% 2,0 .66-9.01 .223
GI virus
Neg 1
Pos 3.56 1.40-9.02 .008
Gender
Female 1
Male .89 .56-1.43 .636
Indication
Malignant 1
Nonmalignant 1.87 .737-4.72 .188
Donor type
MSD/MFD 1 .665
MUD .82 .12-5.8 .839
CB 1.49 .34-6.6 .599
Match grade
Matched 1
Mismatched 1.1 .83-1.47 .494
CI indicates conﬁdence interval; Neg, negative; Pos, positive; MFD, matched
family donor; MUD, matched unrelated donor.
Figure 1. Kaplan-Meier curve depicting virus positivity in stool detected by
PCR in 48 pediatric HCT patients and the cumulative incidence of and intes-
tinal aGVHD.
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of aGVHD has not been described before. It is, however, in
line with the previously reported association between res-
piratory virus PCR positivity in nasopharyngeal aspirates or
in bronchoalveolar lavage ﬂuids and allo-immune lung dis-
ease [5] and with the increased susceptibility for bronchio-
litis obliterans in lung transplantation patients who
encounter viral infections [15]. Previous studies have
addressed the prevalence of viral PCR positivity for common
GI tract viruses in healthy persons and in cancer patients
treated with chemotherapy and reported relatively high
prevalences in the latter category [16,17]. More detailed
studies on the impact of alteration of microbiome, viriome,
and mycome after HCT may give even more detailed infor-
mation on the association with GVHD and could potentially
generate clues for ﬁnding microbiotal intervention strategies
to prevent GVHD.
These results require conﬁrmation in larger studies as
they may affect monitoring and treatment (preventive and
curative) guidelines, as well as decision-making on
rescheduling of elective HCTs until viral clearance. For
example, HCT may be postponed in patients with metabolic
(storage) diseases scheduled for HCTwho have a positive PCR
for GI viruses, given the fact that such patients may be
anticipated to clear common GI viruses within a relatively
short period of time. Knowledge about viral persistence as a
risk factor for aGVHD may also result in more stringent
immune-suppressive therapies to prevent GVHD in GI virus
PCR-positive HCT recipients.
In conclusion, we found PCR positivity for common GI
viruses to be associated with increased intestinal aGVHD. If
conﬁrmed in larger studies, these results may have impor-
tant implications for timing and perhaps rescheduling of
elective HCTs. In addition, these results may ultimately in-
ﬂuence immune-suppressive regimens in GI virusepositive
patients.
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